Literature DB >> 2989523

Synthesis and antiherpetic activity of (S)-, (R)-, and (+/-)-9-[(2,3-dihydroxy-1-propoxy)methyl]guanine, linear isomers of 2'-nor-2'-deoxyguanosine.

W T Ashton, L F Canning, G F Reynolds, R L Tolman, J D Karkas, R Liou, M E Davies, C M DeWitt, H C Perry, A K Field.   

Abstract

Racemic 9-[(2,3-dihydroxy-1-propoxy)methyl]guanine [(+/-)-iNDG], a new analogue of acyclovir (ACV) and a structural analogue of 2'-nor-2'-deoxyguanosine (2'NDG), was synthesized and found to inhibit the replication of herpes simplex virus types 1 (HSV-1) and 2 (HSV-2). Subsequently, its optical isomers, (R)- and (S)-iNDG, were prepared from chiral intermediates. The chloromethyl ethers of 1,2-di-O-benzyl-D- and -L-glycerol were made and reacted with tris(trimethylsilyl)guanine to give the 9-alkylated guanines, which were deprotected by catalytic hydrogenolysis. Against HSV-1 and HSV-2 in cell culture, (S)-iNDG was approximately 10- to 25-fold more active than the R enantiomer and had an ED50 comparable to those for ACV and 2'NDG. The inferior activity of (R)-iNDG paralleled the poor inhibition of viral DNA polymerase by its phosphorylation products. In mice infected intraperitoneally or orofacially with HSV-1 or intravaginally with HSV-2, (S)-9-[(2,3-dihydroxy-1-propoxy)methyl]guanine [(S)-iNDG] was less efficacious than 2'NDG but comparable to or more active than ACV.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2989523     DOI: 10.1021/jm00145a014

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  9 in total

1.  Identification of a developmental chemoattractant in Myxococcus xanthus through metabolic engineering.

Authors:  D B Kearns; A Venot; P J Bonner; B Stevens; G J Boons; L J Shimkets
Journal:  Proc Natl Acad Sci U S A       Date:  2001-11-20       Impact factor: 11.205

2.  Suppression of herpes simplex virus type 1 reactivation from latency by (+-)-9-([(Z)-2-(hydroxymethyl)cyclohexyl]methyl) guanine (L-653,180) in vitro.

Authors:  Y A Nsiah; R L Tolman; J D Karkas; F Rapp
Journal:  Antimicrob Agents Chemother       Date:  1990-08       Impact factor: 5.191

3.  In vitro anti-human immunodeficiency virus activities of Z- and E-methylenecyclopropane nucleoside analogues and their phosphoro-L-alaninate diesters.

Authors:  H Uchida; E N Kodama; K Yoshimura; Y Maeda; P Kosalaraksa; V Maroun; Y L Qiu; J Zemlicka; H Mitsuya
Journal:  Antimicrob Agents Chemother       Date:  1999-06       Impact factor: 5.191

4.  Comparison of the modes of antiviral action of 2'-nor-deoxyguanosine and its cyclic phosphate, 2'-nor-cyclic GMP.

Authors:  J Germershausen; R Bostedor; R Liou; A K Field; A F Wagner; M MacCoss; R L Tolman; J D Karkas
Journal:  Antimicrob Agents Chemother       Date:  1986-06       Impact factor: 5.191

5.  Antiherpesvirus activity of 9-(4-hydroxy-3-hydroxy-methylbut-1-yl)guanine (BRL 39123) in cell culture.

Authors:  M R Boyd; T H Bacon; D Sutton; M Cole
Journal:  Antimicrob Agents Chemother       Date:  1987-08       Impact factor: 5.191

6.  (Z)- and (E)-2-(1,2-dihydroxyethyl)methylenecyclopropane analogues of 2'-deoxyadenosine and 2'-deoxyguanosine. Synthesis of all stereoisomers, absolute configuration, and antiviral activity.

Authors:  Shaoman Zhou; John C Drach; Mark N Prichard; Jiri Zemlicka
Journal:  J Med Chem       Date:  2009-05-28       Impact factor: 7.446

7.  Accessing an azaborine building block: synthesis and substitution reactions of 2-chloromethyl-2,1-borazaronaphthalene.

Authors:  Gary A Molander; Steven R Wisniewski; Javad Amani
Journal:  Org Lett       Date:  2014-10-15       Impact factor: 6.005

8.  An Alternative Approach to Isoganciclovir: A Prominent Impurity in the Antiviral Drug Ganciclovir.

Authors:  Dhanraj T S S Sundaram; Anand G Kamat; Koilpillai Joseph Prabahar; Peruri Badarinadh Gupta; Battula Venkateswara Rao; Sanasi Paul Douglas
Journal:  Sci Pharm       Date:  2014-11-11

9.  Acyclonucleosides: Part 2. diseco-Nucleosides.

Authors:  E S H El Ashry; Y El Kilany
Journal:  Adv Heterocycl Chem       Date:  2008-02-28       Impact factor: 3.552

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.